BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 221 filers reported holding BRIDGEBIO PHARMA INC in Q1 2023. The put-call ratio across all filers is 0.72 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,848 | +78.0% | 108 | +16.1% | 0.00% | – |
| Q2 2023 | $1,600 | -89.2% | 93 | -89.6% | 0.00% | – |
| Q1 2023 | $14,806 | -98.3% | 893 | -99.2% | 0.00% | -100.0% |
| Q4 2022 | $892,758 | -72.2% | 117,160 | -63.7% | 0.00% | -71.4% |
| Q3 2022 | $3,210,000 | +50.1% | 323,196 | +37.1% | 0.01% | +75.0% |
| Q2 2022 | $2,139,000 | +33.9% | 235,757 | +49.8% | 0.00% | +33.3% |
| Q1 2022 | $1,597,000 | -19.0% | 157,398 | +33.0% | 0.00% | 0.0% |
| Q4 2021 | $1,972,000 | -67.2% | 118,315 | -7.7% | 0.00% | -70.0% |
| Q3 2021 | $6,005,000 | -19.7% | 128,156 | +4.4% | 0.01% | -23.1% |
| Q2 2021 | $7,481,000 | +285.2% | 122,745 | +289.1% | 0.01% | +333.3% |
| Q1 2021 | $1,942,000 | -24.7% | 31,543 | -13.0% | 0.00% | -40.0% |
| Q4 2020 | $2,578,000 | +60.1% | 36,269 | -15.6% | 0.01% | +66.7% |
| Q3 2020 | $1,610,000 | +43.1% | 42,949 | +24.3% | 0.00% | 0.0% |
| Q2 2020 | $1,125,000 | – | 34,552 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
| Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
| Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
| Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
| M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
| VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
| BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
| Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
| SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |